<DOC>
	<DOCNO>NCT01492101</DOCNO>
	<brief_summary>The study design open-label , randomize , parallel , two arm , multicenter , international Phase 3 study patient recurrent metastatic breast cancer previously treat cytotoxic chemotherapy regimen . The primary study objective compare overall survival patient receive NKTR-102 give every 21 day patient receive treatment Physician 's Choice select list seven single-agent intravenous therapy .</brief_summary>
	<brief_title>The BEACON Study ( Breast Cancer Outcomes With NKTR-102 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion Criteria ( major highlight ) : Patient adult female histologically cytologically confirm carcinoma breast singleagent cytotoxic chemotherapy indicate Patient either measurable nonmeasurable disease RECIST . Patient receive prior therapy ( administer neoadjuvant , adjuvant and/or metastatic setting ) anthracycline , taxane capecitabine Patient minimum 2 maximum 5 prior cytotoxic chemotherapy regimens last dose administer within 6 month . A minimum two chemotherapy regimen locally recurrent and/or metastatic disease . All therapy receive prior diagnosis metastatic disease ( eg , neoadjuvant , adjuvant repeat adjuvant therapy follow second resection ) count one regimen . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate hematopoietic , liver kidney function . Exclusion Criteria ( major highlight ) : Patient chemotherapy within 21 day , radiotherapy within 14 day , biological therapy 14 day , hormonal therapy within 7 day investigational therapy within 21 day prior randomization . Patient major surgery within 28 day prior randomization . Patient concurrent use biologic agent treatment cancer include antibody investigational agent ( ) . Patient prior treatment cancer camptothecin derivative . Patient chronic acute GI disorder result diarrhea severity grade ; patient use chronic antidiarrheal supportive care control diarrhea 28 day prior randomization . Patient receive pharmacotherapy hepatitis B C , tuberculosis HIV . Patient known cirrhosis diagnose ChildPUGH Class A high liver disease . Patient prior malignancy ( breast cancer ) except nonmelanoma skin cancer carcinoma situ ( cervix bladder ) , unless diagnose definitively treat 5 year prior randomization . Patient require daily use oxygen supplementation 28 day prior randomization . Patients significant cardiovascular impairment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>